REQUEST A DEMO
Total
USD $0.00
View basket Checkout now
Search more companies

Cardiopharm, Spol. S R.O. (Slovakia)

Main Activities: Pharmacies and Drug Stores | Department Stores
Full name: Cardiopharm, Spol. S R.O. Profile Updated: July 10, 2025
Buy our report for this company USD 29.95 Most recent financial data: 2024 Available in: English Download a sample report

Cardiopharm, Spol. S R.O. is an enterprise in Slovakia, with the main office in Banska Bystrica. It operates in the Pharmacies and Drug Stores industry. The company was established on March 06, 2009. 3 - 4 (2025) employees currently work for Cardiopharm, Spol. S R.O.. The latest financial highlights indicate a net sales revenue increase of 10.58% in 2024. Its’ total assets recorded a growth of 99.19%. In 2024, Cardiopharm, Spol. S R.O.’s net profit margin increased by 1.22%.

Headquarters
Kapitulska, 1
Banska Bystrica; Banskobystricky; Postal Code: 97401

Contact Details: Purchase the Cardiopharm, Spol. S R.O. report to view the information.

Basic Information
Total Employees:
Purchase the Cardiopharm, Spol. S R.O. report to view the information.
Registered Capital:
Purchase the Cardiopharm, Spol. S R.O. report to view the information.
Financial Auditors:
Purchase the Cardiopharm, Spol. S R.O. report to view the information.
Incorporation Date:
March 06, 2009
Key Executives
Purchase this report to view the information.
Legal Representative
Ownership Details
Purchase this report to view the information.
100%
Company Performance
Financial values in the chart are available after Cardiopharm, Spol. S R.O. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency EUR. Absolute financial data is included in the purchased report.
Net sales revenue
10.58%▲
Total operating revenue
18.1%▲
Operating profit (EBIT)
507.25%▲
EBITDA
507.25%▲
Net Profit (Loss) for the Period
618.07%▲
Total assets
99.19%▲
Total equity
20.16%▲
Operating Profit Margin (ROS)
1.37%▲
Net Profit Margin
1.22%▲
Return on Equity (ROE)
-22.44%▼
Debt to Equity Ratio
-0.22%▼
Quick Ratio
0.21%▲
Cash Ratio
0%

To view more information, Request a demonstration of the EMIS service

USD 29.95
Buy this company report
Need ongoing access to company, industry or country information?
Request a demo